SG11201500261VA - Prediction of treatment response to jak/stat inhibitor - Google Patents

Prediction of treatment response to jak/stat inhibitor

Info

Publication number
SG11201500261VA
SG11201500261VA SG11201500261VA SG11201500261VA SG11201500261VA SG 11201500261V A SG11201500261V A SG 11201500261VA SG 11201500261V A SG11201500261V A SG 11201500261VA SG 11201500261V A SG11201500261V A SG 11201500261VA SG 11201500261V A SG11201500261V A SG 11201500261VA
Authority
SG
Singapore
Prior art keywords
jak
prediction
treatment response
stat inhibitor
stat
Prior art date
Application number
SG11201500261VA
Inventor
Alexander Cao
Michael Morrissey
Dmitriy Sonkin
Michael Palmer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48906529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201500261V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201500261VA publication Critical patent/SG11201500261VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
SG11201500261VA 2012-07-27 2013-07-24 Prediction of treatment response to jak/stat inhibitor SG11201500261VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261676484P 2012-07-27 2012-07-27
US201361769271P 2013-02-26 2013-02-26
US201361829327P 2013-05-31 2013-05-31
PCT/US2013/051824 WO2014018632A1 (en) 2012-07-27 2013-07-24 Prediction of treatment response to jak/stat inhibitor

Publications (1)

Publication Number Publication Date
SG11201500261VA true SG11201500261VA (en) 2015-02-27

Family

ID=48906529

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500261VA SG11201500261VA (en) 2012-07-27 2013-07-24 Prediction of treatment response to jak/stat inhibitor

Country Status (18)

Country Link
US (1) US20150299796A1 (en)
EP (1) EP2877596A1 (en)
JP (1) JP2015526074A (en)
KR (1) KR20150038241A (en)
CN (1) CN104508149A (en)
AU (2) AU2013295855A1 (en)
BR (1) BR112015001521A2 (en)
CA (1) CA2880198A1 (en)
CL (1) CL2015000192A1 (en)
HK (1) HK1205198A1 (en)
IL (1) IL236897A0 (en)
MX (1) MX2015001269A (en)
PH (1) PH12015500169A1 (en)
RU (1) RU2015106714A (en)
SG (1) SG11201500261VA (en)
TN (1) TN2015000019A1 (en)
TW (1) TW201409030A (en)
WO (1) WO2014018632A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
ES2774448T3 (en) 2014-10-03 2020-07-21 Novartis Ag Combination therapies
TN2017000375A1 (en) 2015-03-10 2019-01-16 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106544414A (en) * 2016-10-09 2017-03-29 广州泰诺迪生物科技有限公司 A kind of method of STAT3 and LCK in detection brain metastasis sample
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME
CN107137701B (en) * 2017-05-07 2020-07-14 山东兴瑞生物科技有限公司 Gene target and inhibitor for improving anti-liver cancer effect of DC vaccine and DC tumor vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US20060194275A1 (en) * 2001-04-13 2006-08-31 Incyte Corporation Transporter and ion channels
EP2350317A4 (en) * 2008-10-20 2012-06-27 Univ Colorado Regents Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2763900A1 (en) * 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
AU2011335882B2 (en) * 2010-12-03 2016-03-10 Ym Biosciences Australia Pty Ltd Treatment of JAK2-mediated conditions

Also Published As

Publication number Publication date
TN2015000019A1 (en) 2016-06-29
TW201409030A (en) 2014-03-01
BR112015001521A2 (en) 2017-11-07
US20150299796A1 (en) 2015-10-22
JP2015526074A (en) 2015-09-10
MX2015001269A (en) 2015-05-08
AU2013295855A1 (en) 2015-02-12
AU2017204894A1 (en) 2017-08-03
PH12015500169A1 (en) 2015-03-16
EP2877596A1 (en) 2015-06-03
IL236897A0 (en) 2015-03-31
CN104508149A (en) 2015-04-08
CL2015000192A1 (en) 2015-06-26
CA2880198A1 (en) 2014-01-30
RU2015106714A (en) 2016-09-20
HK1205198A1 (en) 2015-12-11
WO2014018632A1 (en) 2014-01-30
KR20150038241A (en) 2015-04-08

Similar Documents

Publication Publication Date Title
IL255045A0 (en) Crystal of flumioxazin
HK1205198A1 (en) Prediction of treatment response to jak/stat inhibitor jak/stat
EP2822897A4 (en) Treatment of industrial water systems
EP2723384A4 (en) Treatment of proteinopathies
IL287057A (en) Purification of iduronate-2 sulfatase
SG10201510800PA (en) Purification of flaviviruses
EP2867792A4 (en) Performance of predicted actions
DK2928477T3 (en) USE OF TELETOMERASE INHIBITOR IMETELSTAT TO TREAT MYELOFIBROSIS
EP2881113A4 (en) New application of pogostone
EP2709665A4 (en) Treatment of psoriasis
EP2892529A4 (en) Uses of (-)-perhexiline
HK1210937A1 (en) Use of pidotimod to treat psoriasis
IL259184B (en) Crystal of flumioxazin
ZA201500297B (en) Prediction of treatment response to jak/stat inhibitor
GB201212717D0 (en) Treatment of musculoskeletal conditions
TWM433525U (en) Structure of calorifier